Source: Davit Kirakosyan
UBS Maintains a Positive Outlook on Johnson & Johnson Despite Legal Challenges
Despite the ongoing legal challenges faced by Johnson & Johnson (NYSE:JNJ) in its talc litigation saga, Swiss multinational investment bank and financial services company, UBS, has reaffirmed its Buy rating on the company. The bank has also maintained a $180 price target. The ongoing talc litigation saga has, however, raised concerns about potential short-term volatility risks, especially following the latest legal setback for the pharmaceutical and consumer packaged goods manufacturing company.
In a recent development, the courts rejected Johnson & Johnson’s attempt to use bankruptcy proceedings as a mechanism to resolve current and future talc-related lawsuits. This was the third time the company’s attempt was rejected, despite reportedly having over 75% support from claimants. UBS notes that this development has significantly impacted investor sentiment and has triggered concerns ahead of the company’s first-quarter earnings release. Any performance less than robust execution could potentially trigger a disproportionate market reaction.
UBS’s Confidence in Johnson & Johnson’s 2025 Fundamentals
Despite the prevailing challenges, UBS analysts remain confident in Johnson & Johnson’s fundamentals going into 2025. They attributed their confidence to the company’s steady performance in the face of the loss of exclusivity on Stelara, a key immunology drug. The analysts further pointed out that the recently closed acquisition of Intra-Cellular Therapies (ITCI) could act as a potential growth driver for the company.
Impact of Medicare Part D Redesign on J&J’s Earnings
A key area of investor focus this quarter will be the impact of the Medicare Part D redesign on Johnson & Johnson. The redesign introduces new cost-sharing dynamics that could potentially affect the company’s revenues. UBS flagged that consensus estimates may still be misaligned on the earnings implications for specific J&J drugs due to the redesign.
Performance of Tremfya Bolsters Optimism
Despite the near-term uncertainty, optimism surrounds the performance of Tremfya, the company’s psoriasis and inflammatory bowel disease drug. Tremfya saw a 14% quarter-over-quarter growth in total prescriptions, thanks to its ulcerative colitis (UC) launch. UBS anticipates further upside as Tremfya expands into the Crohn’s disease (CD) market with a unique subcutaneous-only dosing regimen, setting it apart from its competitors.
Future Outlook on Johnson & Johnson
While short-term sentiment may be swayed by the upcoming earnings call, UBS firmly believes that Johnson & Johnson’s broad pipeline, ongoing innovation, and defensive business mix keep it well positioned for longer-term upside. Despite the looming legal challenges, the company’s strategic moves, continued innovation, and strong fundamentals underscore the potential for sustainable growth and bolster investor optimism about the company’s future.
In conclusion, while the talc litigation saga presents a short-term challenge, Johnson & Johnson’s strategic acquisitions, robust drug performance, and ongoing innovation in the midst of legal and financial challenges solidify UBS’s confidence in the company’s long-term growth prospects. Investors and market watchers are eagerly awaiting the company’s first-quarter earnings call to gauge the impact of these factors on its financial performance.